HHLA2 在实体瘤患者中的预后价值：一项荟萃分析。

Prognostic Value of HHLA2 in Patients with Solid Tumors: A Meta-Analysis.

机构信息

Department of Oncological Surgery, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-808 Katowice, Poland.

Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-800 Zabrze, Poland.

出版信息

Int J Mol Sci. 2024 Apr 26;25(9):4760. doi: 10.3390/ijms25094760.

DOI:10.3390/ijms25094760

PMID:38731979

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11083681/

Abstract

HHLA2 is a checkpoint from the B7 family that can play a co-stimulatory or co-inhibitory role in cancer, depending on the binding receptor. The aim of this meta-analysis was to assess the relationship between HHLA2 levels and its impact on the prognosis of patients with solid cancers. The study used data from PubMed, Embase, Web of Science (WOS), Cochrane and SCOPUS databases. The R studio software was used for the data analysis. The study assessed overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), recurrence-free survival (RFS), and disease-free survival (DFS) by pooling appropriate hazard ratios (HR). Eighteen studies (2880 patients' data) were included. High expression of HHLA2 was associated with worse OS (HR = 1.58, 95% CI: 1.23-2.03), shorter RFS (HR = 1.95, 95% CI: 1.38-2.77) and worse DFS (HR = 1.45, 95% CI: 1.01-2.09) in patients with solid cancers. The current study suggests that high expression of HHLA2 is associated with poorer prognosis in patients with solid cancers.

摘要

HHLA2 是 B7 家族的一个检查点，在癌症中可以发挥共刺激或共抑制作用，具体取决于结合受体。本荟萃分析的目的是评估 HHLA2 水平与实体瘤患者预后之间的关系。该研究使用了来自 PubMed、Embase、Web of Science(WOS)、Cochrane 和 SCOPUS 数据库的数据。使用 R 工作室软件进行数据分析。该研究通过汇总适当的风险比 (HR) 评估了总生存期 (OS)、疾病特异性生存期 (DSS)、无进展生存期 (PFS)、无复发生存期 (RFS) 和无病生存期 (DFS)。纳入了 18 项研究（2880 名患者的数据）。HHLA2 高表达与 OS 较差相关（HR=1.58，95%CI：1.23-2.03）、RFS 较短（HR=1.95，95%CI：1.38-2.77）和 DFS 较差（HR=1.45，95%CI：1.01-2.09）。目前的研究表明，HHLA2 高表达与实体瘤患者的预后较差相关。